BACKGROUND: The management of severe occupational asthma (OA) remains problematic and new alternative treatments providing better disease control are required, ideally enabling affected individuals to remain in their job. METHODS: Ten patients with severe uncontrolled OA were treated with the monoclonal anti-IgE antibody omalizumab. In six cases the causative agent was a high molecular weight (HMW) compound and in four cases it was a low molecular weight (LMW) chemical. All of the patients had well documented OA despite workplace adjustments. RESULTS: During treatment, nine patients exhibited a lower rate of asthma exacerbations and used less oral or inhaled corticosteroids. Seven patients were able to continue working at the same workplace as before treatment. CONCLUSION: We have demonstrated that omalizumab is a potential treatment for severe uncontrolled OA and enabled seven of the ten patients in the study to remain in their job.
BACKGROUND: The management of severe occupational asthma (OA) remains problematic and new alternative treatments providing better disease control are required, ideally enabling affected individuals to remain in their job. METHODS: Ten patients with severe uncontrolled OA were treated with the monoclonal anti-IgE antibody omalizumab. In six cases the causative agent was a high molecular weight (HMW) compound and in four cases it was a low molecular weight (LMW) chemical. All of the patients had well documented OA despite workplace adjustments. RESULTS: During treatment, nine patients exhibited a lower rate of asthma exacerbations and used less oral or inhaled corticosteroids. Seven patients were able to continue working at the same workplace as before treatment. CONCLUSION: We have demonstrated that omalizumab is a potential treatment for severe uncontrolled OA and enabled seven of the ten patients in the study to remain in their job.
Authors: Jean-Luc Malo; Susan M Tarlo; Joaquin Sastre; James Martin; Mohamed F Jeebhay; Nicole Le Moual; Dick Heederik; Thomas Platts-Mills; Paul D Blanc; Olivier Vandenplas; Gianna Moscato; Frédéric de Blay; André Cartier Journal: Ann Am Thorac Soc Date: 2015-07
Authors: Matteo Ferrando; Diego Bagnasco; Gilda Varricchi; Stefano Bernardi; Alice Bragantini; Giovanni Passalacqua; Giorgio Walter Canonica Journal: Allergy Asthma Immunol Res Date: 2017-01 Impact factor: 5.764
Authors: Angelica I Tiotiu; Silviya Novakova; Marina Labor; Alexander Emelyanov; Stefan Mihaicuta; Plamena Novakova; Denislava Nedeva Journal: Int J Environ Res Public Health Date: 2020-06-24 Impact factor: 3.390
Authors: Vanessa De Vooght; Vincent Carlier; Fien C Devos; Steven Haenen; Erik Verbeken; Benoit Nemery; Peter H M Hoet; Jeroen A J Vanoirbeek Journal: PLoS One Date: 2013-12-13 Impact factor: 3.240